
CLAIMS


What is claimed is:

1. ~~A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~


~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks.~~ Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),


or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein the medicament is to be orally administered for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks.

2. ~~A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~


~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient~~. Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),


or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the subject.

3. ~~A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic~~ kidney disease ~~comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~


~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL~~. Use of of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),


or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.

4. ~~A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic~~ kidney disease ~~a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound 1),~~


~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks~~. Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein the medicament is to be orally administered for at least about 53-260 weeks.


5. ~~A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient~~. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 4, wherein hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the subject.


6. ~~A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 4, wherein hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.


7. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

or a pharmaceutically acceptable salt thereof, obtaining the patient's hemoglobin (Hb) level, and adjusting the dose by about 150 mg of Compound 1 if the patient's hemoglobin (Hb) level is < 11.0 g/dL or > 11.5 g/dL.

8. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

or a pharmaceutically acceptable salt thereof, obtaining the patient's hemoglobin (Hb) level, and decreasing the dose by about 150 mg of Compound 1 if the patient's hemoglobin (Hb) level increases by > 1.0 g/dL in a 2-week period or by > 2.0 g/dL in a 4-week period.

9.7. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to method of any one of claims 1-3, wherein the medicamentdose of Compound 1 is to be administered to the subjectpatient for at least about 24 weeks.

~~10.~~8. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-3, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 28 weeks.

~~11.~~9. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-3, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 32 weeks.

~~12.~~10. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-3, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 36 weeks.

~~13.~~11. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-3, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 40 weeks.

~~14.~~12. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-3, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 44 weeks.

~~15.~~13. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-3, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 48 weeks.

~~16.~~14. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-3, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 52 weeks.

~~17.~~15. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 53 weeks.

~~18.~~16. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 64 weeks.

~~19.~~17. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 76 weeks.

~~20.~~18. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 88 weeks.

~~21.~~19. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 104 weeks.

~~22.~~20. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 116 weeks.

~~23.~~21. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 128 weeks.

~~24.~~22. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 140 weeks.

~~25.~~23. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 156 weeks.

~~26.~~24. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 168 weeks.

~~27.~~25. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 180 weeks.

~~28.~~26. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 192 weeks.

~~29.~~27. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 208 weeks.

~~30.~~28. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 4-6, wherein the medicament~~dose of Compound 1~~ is to be administered to the subject~~patient~~ for at least about 260 weeks.

~~31.~~29. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-28~~30~~, wherein the subject~~patient~~ has non-dialysis dependent chronic kidney disease (NDD-CKD).

~~32.~~30. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-28~~30~~, wherein the subject~~patient~~ has dialysis-dependent chronic kidney disease (DD-CKD).

~~33.~~31. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-30~~2~~, wherein the subject~~patient~~ has been previously treated with an erythropoiesis stimulating agent (ESA).

~~34.~~32. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 31~~3~~, wherein the subject~~patient~~ has been previously treated with an erythropoiesis stimulating agent (ESA) within about eight weeks prior to or during a screening period before administering the medicament~~a dose of Compound 1~~.

~~35.~~33. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 31~~3~~, wherein the subject~~patient~~ has been previously treated with an erythropoiesis stimulating agent (ESA) within about six weeks prior to or during a screening period before administering the medicament~~a dose of Compound 1~~.

~~36.~~34. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 32~~4~~ or 33~~5~~, wherein the screening period is up to about eight weeks.

~~37.~~35. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 32~~4~~ or 33~~5~~, wherein the screening period is up to about 6 weeks.

~~38.~~36. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 32~~4~~ or 33~~5~~, wherein the screening period is up to about 4 weeks.

~~39.~~37. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 31~~3~~-36~~8~~, wherein the erythropoiesis stimulating agent is epoetin, darbepoetin alfa (DA), or methoxy polyethylene glycol-epoetin beta (epoetin beta pegol).

~~40.~~38. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~9~~, wherein the epoetin is epoetin alfa, epoetin beta, epoetin gamma, epoetin kappa, or a combination thereof.

~~41. The method of claim 39, wherein the erythropoiesis stimulating agent is darbepoetin alfa.~~

~~42. The method of claim 39, wherein the erythropoiesis stimulating agent is methoxy polyethylene glycol-epoetin beta (epoetin beta pegol).~~

~~43.~~39. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 38~~40~~, wherein the subject~~patient~~ has been previously treated with epoetin alfa in an amount of about 10 U/kg to about 500 U/kg 3 times weekly.

~~44. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to method of claim 40, wherein the patient has been previously treated with epoetin alfa in an amount of about 10 U/kg to about 300 U/kg 3 times weekly.~~

~~45. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to method of claim 40, wherein the patient has been previously treated with epoetin alfa in an amount of about 50 U/kg to about 300 U/kg 3 times weekly.~~

~~46. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to method of claim 40, wherein the patient has been previously treated with epoetin alfa in an amount of about 50 U/kg to about 100 U/kg 3 times weekly.~~

~~47.~~40. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~42~~, wherein the subject~~patient~~ has been previously treated with epoetin beta pegol in a dosage amount of about 0.6 mcg/kg to about 1.20 mcg/kg once every two weeks.

~~48.~~41. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~42~~, wherein the subject~~patient~~ has been previously treated with epoetin beta pegol in a dosage amount of about 0.6 mcg/kg to about 1.20 mcg/kg once monthly.

~~49. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to method of claim 42, wherein the patient has been previously treated with epoetin beta pegol in a dosage amount of about 0.6 mcg/kg once every two weeks.~~

~~50. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to method of claim 42, wherein the patient has been previously treated with epoetin beta pegol in a dosage amount of about 1.2 mcg/kg once every two weeks.~~

~~51.~~42. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~9~~, wherein the subject~~patient~~ has been previously treated with epoetin at a dose of about ≥ 4500 IU weekly.

~~52.~~43. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 3~~79~~, wherein the subject~~patient~~ has been previously treated with epoetin at a dose of about <4500 IU.

~~53.~~44. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~41~~, wherein the subject~~patient~~ has been previously treated with darbepoetin alfa (DA) in a dosage amount of about 0.45 mcg/kg to about 0.75 mcg/kg once every four weeks.

~~54.~~45. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~41~~, wherein the subject~~patient~~ has been previously treated with darbepoetin alfa (DA) in a dosage amount of about 0.45 mcg/kg to about 0.75 mcg/kg once every two weeks.

~~55.~~46. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~41~~, wherein the subject~~patient~~ has been previously treated with darbepoetin alfa (DA) in a dosage amount of about 0.45 mcg/kg to about 0.75 mcg/kg once a week.

~~56.~~47. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~41~~, wherein the subject~~patient~~ has been previously treated with darbepoetin alfa in a dosage amount of about ≥ 15 µg weekly.

~~57.~~48. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 37~~41~~, wherein the subject~~patient~~ has been previously treated with darbepoetin alfa in a dosage amount of about < 15 µg weekly.

~~58.~~49. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-30~~2~~, wherein the subject~~patient~~ has not been previously treated with an erythropoiesis stimulating agent (ESA).

~~59.~~50. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-49~~58~~, wherein the medicament~~dose~~ is to be administered at a dosage comprising~~comprises~~ about 150-600 mg ~~of Compound 1~~.

~~60.~~51. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-50~~59~~, wherein the medicament~~dose~~ is to be administered at a dosage comprising~~comprises~~ about 150 mg ~~of Compound 1~~.

~~61.~~52. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-50~~59~~, wherein the medicament~~dose~~ is to be administered at a dosage comprising~~comprises~~ about 300 mg ~~of Compound 1~~.

~~62.~~53. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-50~~59~~, wherein the medicament~~dose~~ is to be administered at a dosage comprising~~comprises~~ about 450 mg ~~of Compound 1~~.

~~63.~~54. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-50~~59~~, wherein the medicament~~dose~~ is to be administered at a dosage comprising~~comprises~~ about 600 mg ~~of Compound 1~~.

~~64.~~55. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-54~~63~~, wherein the medicament~~dose of Compound 1~~ is to be administered once daily.

~~65.~~56. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-54~~63~~, wherein the medicament~~dose of Compound 1~~ is to be administered once a week.

~~66.~~57. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-54~~63~~, wherein the medicament~~dose of Compound 1~~ is to be administered three times a week.

~~67.~~58. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-50~~59~~, wherein the medicament is to be ~~dose comprises about 300 mg of Compound 1, and the dose is~~ administered once daily.

~~68.~~59. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-5~~8~~9, wherein the medicament is to be ~~dose comprises about 450 mg of Compound 1, and the dose is~~ administered three times a week.

~~69.~~60. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1, 4 and 7-59~~-68~~, wherein the subject~~patient~~ has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL.

~~70. The method of any one of claims 1, 4 and 9-68, wherein the patient has a hemoglobin level of about 8.0 g/dL to about 12.0 g/dL.~~

~~71. The method of any one of claims 1, 4 and 9-68, wherein the patient has a hemoglobin level of about 8.0 g/dL to about 11.0 g/dL.~~

~~72. The method of any one of claims 1, 4 and 9-68, wherein the patient has a hemoglobin level of about 9.0 g/dL to about 12.0 g/dL.~~

~~73. The method of any one of claims 1, 4 and 9-68, wherein the patient has a hemoglobin level of about 9.5 g/dL to about 12.0 g/dL.~~

~~74. The method of any one of claims 1, 4 and 9-68, wherein the patient has a hemoglobin level of about 9.0 g/dL to about 12.5 g/dL.~~

~~75. The method of any one of claims 7 and 9-68, wherein the patient has a hemoglobin level of about <11.0 g/dL.~~

~~76. The method of any one of claims 7 and 9-68, wherein the patient has a hemoglobin level of about >11.5 g/dL.~~

~~77. The method of any one of claims 7 and 9-68, wherein the patient has a hemoglobin level of about ≥9.5 g/dL to about <11.0 g/dL.~~

~~78. The method of any one of claims 7 and 9-68, wherein the patient has a hemoglobin level of about ≥8.0 g/dL to about <11.0 g/dL.~~

~~79. The method of any one of claims 7 and 9-68, wherein the patient has a hemoglobin level of about ≥12.0 g/dL.~~

~~80.~~61. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims ~~7 and~~ 7-59~~9-68~~, wherein the subject~~patient~~ has a hemoglobin level of about ≥13.0 g/dL.

~~81.~~62. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-61~~80~~, wherein the subject~~patient~~ has a baseline hemoglobin level of about <10 g/dL.

~~82. The method of any one of claims 1-80, wherein the patient has a baseline hemoglobin level of about ≤9 g/dL.~~

~~83. The method of any one of claims 1-80, wherein the patient has a baseline hemoglobin level of about ≤8 g/dL.~~

~~84. The method of any one of claims 2, 5, 9-68 and 81-83, wherein the hemoglobin levels are increased to about 10.0-12.0 g/dL.~~

~~85.~~63. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 2, 5, ~~9-68~~7-59 and ~~81-83~~62, wherein the hemoglobin levels are increased to about 10.0-11.0 g/dL.

~~86.~~64. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 2, 5, 7-59 ~~9-68~~ and 62~~81-83~~, wherein the hemoglobin levels are increased to about 11.0-13.0 g/dL.

~~87.~~65. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 7-59 ~~7, 9-68~~ and ~~81-83~~62, wherein the medicament is to be administered comprising~~method comprises~~ adjusting the dosage~~e~~ by about 150 mg ~~of Compound 1~~ if the subject~~patient~~'s hemoglobin (Hb) level is < 10.0 g/dL or > 11.5 g/dL.

~~88. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to method of any one of claims 7, 9-68 and 81-83, wherein the method comprises adjusting the dose by about 150 mg of Compound 1 if the patient's hemoglobin (Hb) level is < 10.0 g/dL or > 12.5 g/dL.~~

~~89. The method of any one of claims 7, 9-68 and 81-83, wherein the method comprises adjusting the dose by about 150 mg of Compound 1 if the patient's hemoglobin (Hb) level is < 10.0 g/dL.~~

~~90.~~66. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 65~~89~~, wherein the medicament is to be administered further ~~adjusting the dose~~ comprising~~es~~ increasing the dosage~~e by about 150 mg~~, and the subject's hemoglobin (Hb) level is < 10.0 g/dL ~~of Compound 1~~.

~~91. The method of any one of claims 7, 9-68 and 81-83, wherein the method comprises adjusting the dose by about 150 mg of Compound 1 if the patient's hemoglobin (Hb) level is > 11.5 g/dL.~~

~~92.~~67. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ claim 65~~91~~, wherein the medicament is to be administered further ~~adjusting the dose comprises~~ decreasing the dosage ~~by about 150 mg of Compound 1~~.

~~93.~~68. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims ~~7, 9-68~~7-59, ~~81-83~~62, and ~~87-92~~65-67, wherein the medicament is to be administered further comprising adjusting the dosage ~~occurs~~ no more than once in at least every 2 weeks.

~~94.~~69. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 7-59~~7, 9-68~~, 62~~81-83~~, and 65-67~~87-92~~, wherein the medicament is to be administered further comprising adjusting the dosage ~~occurs~~ no more than once in at least every 4 weeks.

~~95.~~70. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 7-59~~7, 9-68~~, 62~~81-83~~, and 65-67~~87-92~~, wherein the medicament is to be administered further comprising adjusting the dosage ~~occurs~~ no more than once in at least every 6 weeks.

~~96.~~71. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 7-59~~8, 9-68~~ and 62~~81-83~~, wherein the medicament is to be administered further comprising decreasing the dose ~~occurs~~ no more than once in at least every 2 weeks.

~~97. The method of any one of claims 3, 6, 9-68 and 81-83, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.~~

~~98.~~72. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 3, 6, 7-59~~9-68~~ and 62~~81-83~~, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 12.0 g/dL.

~~99.~~73. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 3, 6, 7-59~~9-68~~ and 62~~81-83~~, wherein the hemoglobin levels are maintained or controlled at about 11.0 – 13.0 g/dL.

~~100. The method of any one of claims 3, 6, 9-68 and 81-83, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 11.0 g/dL.~~

~~101.~~74. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-73~~100~~, wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.

~~102. The method of claim 101, wherein the patient has a serum ferritin level of about ≥ 100 ng/mL.~~

~~103. The method of claim 101, wherein the patient has a transferrin saturation (TSAT) of about ≥ 20%.~~

~~104. The method of claim 101, wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and a transferrin saturation (TSAT) of about ≥ 20%.~~


~~105.~~75. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-74~~104~~, wherein the patient has a decrease in serum ferritin level relative to a baseline level.

~~106. The method of any one of claims 1-105, wherein the patient is an adult.~~

~~107.~~76. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to ~~method of~~ any one of claims 1-75~~106~~, wherein the patient is ≥ 18 years old.

~~108. The method of any one of claims 1-106, wherein the patient is ≥ 20 years old.~~


~~109. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks.~~


~~110. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.~~


~~111. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~


~~112. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.~~


~~113. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.~~


~~114. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~


~~115. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered three times a week.


116. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.


117. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once a week.


118. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered three times a week.

119. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound 1),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL.

120. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound 1),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.


121. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.~~

~~122. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~

~~123. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.~~

~~124. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.~~

~~125. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.~~

~~126. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once a week.~~

~~127. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




(Compound **1**),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.


128. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof, obtaining the patient's hemoglobin (Hb) level, and adjusting the dose by about 150 mg of Compound **1** if the patient's hemoglobin (Hb) level is < 10.0 g/dL or > 11.5 g/dL.


129. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof, obtaining the patient's hemoglobin (Hb) level, and adjusting the dose by about 150 mg of Compound **1** if the patient's hemoglobin (Hb) level is < 10.0 g/dL or > 12.5 g/dL.


130. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.


131. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound 1, wherein the dose is administered once daily, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.

132. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound 1, wherein the dose is administered once a week, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.

133. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a


~~compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered three times a week, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.~~


~~134. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once daily, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.~~


~~135. A method of increasing levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once a week, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.~~


~~136. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered three times a week, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.~~


~~137. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-250 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once daily, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.~~

~~138. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once a week, and~~

~~wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.~~


~~139. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered three times a week, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the patient.~~


~~140. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~
~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, and wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL from the baseline hemoglobin level in the patient.~~

~~141. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.~~

~~142. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~

~~143. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.~~

144. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound **1**),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.

145. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound **1**),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.

146. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound **1**),

or a pharmaceutically acceptable salt thereof,

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~

~~147. A method of increasing hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are increased to about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.~~


~~148. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA).~~


~~149. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the patient previously has been treated with an erythropoiesis stimulating agent (ESA).~~


~~150. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the patient previously has been treated with an erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg, and wherein the dose is administered once daily.~~


~~151. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~

~~152. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein~~

~~the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.~~


~~153. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.~~


~~154. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~

~~155. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA),~~

~~wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.~~


~~156. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA).~~


~~157. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.~~


~~158. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once a week.~~


~~159. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.~~


~~160. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, wherein the patient has been previously treated with an erythropoiesis stimulating agent (ESA), and wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL.~~


~~161. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.~~

~~162. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once a week.~~

~~163. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered three times a week.~~

~~164. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), and wherein the~~

~~patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.~~

~~165. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.~~

~~166. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once a week.~~

~~167. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




(Compound 1),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL, wherein the patient has been previously treated with erythropoiesis stimulating agent (ESA), and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered three times a week.


168. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.

169. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound 1),

or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound 1, wherein the dose is administered once daily, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.

170. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the


patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once a week, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.


171. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof, for at least about 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered three times a week, and wherein the hemoglobin levels are maintained or controlled about 10.0 – 13.0 g/dL.


172. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once daily, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.


~~173. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once a week, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.~~


~~174. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered three times a week, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.~~


~~175. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once daily, and wherein the hemoglobin levels maintained or controlled at about 10.0 – 13.0 g/dL.~~


~~176. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered once a week, and wherein the hemoglobin levels maintained or controlled at about 10.0 – 13.0 g/dL.~~


~~177. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,~~



~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof, for at least about 53-260 weeks, wherein the dose comprises about 150-600 mg of Compound **1**, wherein the dose is administered three times a week, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.~~

~~178. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound **1**),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, and wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.~~

~~179. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once daily.~~

~~180. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once a week.~~

~~181. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




(Compound **1**),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered three times a week.

182. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound **1**),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.

183. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,




(Compound **1**),

or a pharmaceutically acceptable salt thereof,

wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound **1**, and wherein the dose is administered once daily.

~~184. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered once a week.~~

~~185. A method of maintaining or controlling hemoglobin levels in a patient having anemia associated with or secondary to chronic kidney disease comprising orally administering to the patient a dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

~~or a pharmaceutically acceptable salt thereof,~~

~~wherein the patient has a baseline hemoglobin level of about < 10 g/dL, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL, and wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%, wherein the dose comprises about 150-600 mg of Compound 1, and wherein the dose is administered three times a week.~~

~~186. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease an initial dose of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,~~




~~(Compound 1),~~

or a pharmaceutically acceptable salt thereof, wherein

the patient previously has been treated with an erythropoiesis stimulating agent (ESA), and the initial dose of Compound **1** is selected based on the ESA previously received by the patient, the dosage amount of an ESA previously received by the patient, the patient's hemoglobin (Hgb) levels, and/or the dialysis status of the patient.

187. A method of treating anemia comprising orally administering to a patient having anemia associated with or secondary to chronic kidney disease a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound 1,



(Compound **1**),

or a pharmaceutically acceptable salt thereof, wherein

the patient previously has been treated with an erythropoiesis stimulating agent (ESA), and the patient receives an increase in the dose of Compound **1** within about six weeks after commencing treatment with Compound **1** based on the ESA previously received by the patient, the dosage amount of an ESA previously received by the patient, the patient's hemoglobin (Hgb) levels, and/or the dialysis status of the patient.